Tumor Necrosis Factor Inhibitor Drugs Market

Global Tumor Necrosis Factor Inhibitor Drugs Market Size, Share & Trends Analysis Report, By Product (Humira, Enbrel, Remicade, Simponi, Cimzia, and Others), By Application (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, and Others), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025331 | Category : Pharmaceuticals | Delivery Format: /

The global tumor necrosis factor inhibitor drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). New product launches, a promising pipeline, an increase in the incidence of autoimmune diseases, and a large increase in consumer knowledge of tumor necrosis factor are likely to fuel the growth (TNF) of the market. TNF inhibitors are used to treat inflammatory and autoimmune disorders such as rheumatoid arthritis, psoriasis, Crohn's disease, and cancer, among others, by suppressing the inflammatory response generated by TNF cytokines. The role of TNF inhibitors in the treatment of metastatic melanomas and locally progressed soft tissue sarcomas is under research. Biosimilars provide a direct challenge to biologics in the TNF inhibitor market. 

Biosimilars are becoming more common due to the loss of patent exclusivity in several regions. In addition, Interleukin (IL) inhibitors are a fierce competitor in the market. In multiple head-to-head clinical trials, IL inhibitors have been shown to have improved safety and effectiveness profiles, as well as superior results. A considerable paradigm shift in the treatment of autoimmune disorders has been noted, owing to biologics' focused activity and the emergence of biosimilars. Consumer desire for low-cost pharmaceuticals with enhanced safety and efficacy profiles is likely to boost the market growth.

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape: AbbVie Inc.; Johnson & Johnson Services, Inc.; Novartis International AG; Pfizer, Inc.; and Merck & Co., Inc among others. 

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Tumor Necrosis Factor Inhibitor Drugs Market Report Segmentation

By Product

Humira

Enbrel

Remicade

Simponi

Cimzia

Others

By Application 

Rheumatoid Arthritis

Psoriasis

Psoriatic Arthritis

Crohn’s Disease

Ulcerative Colitis

Others 

Global Tumor Necrosis Factor Inhibitor Drugs Market by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World